FDA approves GlaxoSmithKline’s Nucala drug for severe asthma
Nucala is approved as an add-on maintenance treatment for patients aged 12 and older. It is administered once every four weeks by injection. The drug is a monoclonal
Ray Therapeutics has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) for its RTx-015 gene therapy to treat retinitis pigmentosa (RP).
Both technologies originate from the pioneering work of Don J. Diamond, Ph.D., chair of the Department of Experimental Therapeutics at City of Hope, an independent biomedical research institution
The objective is to develop an original and non-invasive therapeutic medical device for children with ADHD. Developed in close collaboration with neuroscientists and clinicians, the personalized medical solution